We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
AngioDynamics delivered stronger-than-expected Q1 revenue and a narrower adjusted loss per share.
NanoKnife drives growth with FDA clearance, rising disposable sales and future reimbursement catalysts.
Auryon, AlphaVac and AngioVac growth plus steady legacy products support a resilient revenue base.
AngioDynamics (ANGO - Free Report) has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid first-quarter fiscal 2026 performance, positive ongoing studies and a broad product line, bodes well for the stock.
In the year-to-date period, the Zacks Rank #3 (Hold) company’s shares have gained 24.8% compared with 1.1% growth of the industry. The S&P 500 has increased 14.2% during the said time frame.
The renowned designer, manufacturer and seller of an extensive range of innovative medical, surgical and diagnostic devices has a market capitalization of $490.3 million. The company projects 35.7% growth over the next year and expects to witness continued improvements in its business. AngioDynamics’ earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 73.1%.
Image Source: Zacks Investment Research
Reasons Favoring ANGO’s Growth
NanoKnife Driving Growth: NanoKnife continues to be a major growth engine for AngioDynamics, backed by strong clinical adoption and expanding use in prostate cancer. In the first quarter of fiscal 2026, management highlighted more than 25% revenue growth and more than 31% probe growth, driven largely by prostate procedures.
With physicians increasingly adopting the technology ahead of the new CPT Category I code going live on Jan. 1, 2026, the company is also supporting demand through a new AARP awareness campaign. Management believes NanoKnife is well-positioned to become a leading focal therapy choice for intermediate-risk prostate cancer due to strong outcomes, quick procedures and an FDA-cleared, next-generation platform.
The biggest catalyst ahead lies in reimbursement. Prostate procedures will benefit from CPT Category I codes in January 2026, with pancreatic procedures following in January 2027, setting up a stronger recurring revenue model as utilization expands. Combined with a growing installed base, rising surgeon engagement and improved clarity around payments, AngioDynamics sees NanoKnife as a differentiated and durable driver of long-term profitable growth.
Broad Product Line: AngioDynamics continues to demonstrate strong momentum across its Med Tech platforms, led by robust growth in Auryon, thrombectomy and its comprehensive oncology portfolio. In the first quarter of fiscal 2026, Auryon delivered 20.1% revenue growth, its 17th straight quarter of double-digit expansion — supported by solid adoption in both hospitals and OBLs, with the recent CE Mark contributing additional lift.
Thrombectomy remained another standout, with Mechanical Thrombectomy revenue up 41.2%, driven by 37.1% growth in AngioVac and 52.3% in AlphaVac. The expansion of the dedicated thrombectomy sales force to 50 territories highlights the company’s commitment to strengthening market penetration even without major new product launches.
Meanwhile, AngioDynamics’ broader Med Device portfolio delivered stable 2.3% growth, aligning with expectations for low-single-digit expansion. This steady performance complements the faster-growing Med Tech businesses, creating a balanced mix of innovation-led growth and recurring revenue stability. Together, these trends reflect a strengthening competitive position across oncology, vascular access and peripheral disease solutions, underscoring the company’s ability to scale utilization and capture market share across core markets.
Solid Q1 Results: AngioDynamics delivered a solid start to fiscal 2026, with first-quarter revenues rising 12.2% year over year, led by continued strength in its Med Tech segment, which grew 26% and now represents nearly half of total sales. The company also reported a narrower-than-expected adjusted loss, supported by gross margin expansion despite the impact of tariff headwinds.
A Factor That May Offset ANGO’s Gains
Macroeconomic Concerns: In the first quarter of fiscal 2026, AngioDynamics emphasized that tariffs remain the biggest external drag on margins, with $1.7 million in tariff costs weighing on gross margin by about 220 basis points. These expenses were fully expected and aligned with the company’s forecast of $4–$6 million in tariff impact for the full year.
Despite this headwind, gross margin still improved year over year, driven by stronger pricing, operational efficiencies and a mix shift toward higher-margin Med Tech products. Management also pulled forward several cost-improvement initiatives, helping blunt the effect of tariffs and demonstrating solid operational discipline.
Estimate Trend
AngioDynamics has been witnessing a positive estimate revision trend for fiscal 2026. Over the past 30 days, the Zacks Consensus Estimate for loss has narrowed 2 cents to 28 cents per share.
The Zacks Consensus Estimate for second-quarter fiscal 2026 revenues is pegged at $76.1 million, implying a 4.4% rise from the year-ago reported number. The consensus mark for fiscal second-quarter loss per share is pinned at 10 cents, implying a 150% decline year over year.
Key Picks
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , Intuitive Surgical (ISRG - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 14.28%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted EPS of $2.40, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion outperformed the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
Key Takeaways
AngioDynamics (ANGO - Free Report) has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid first-quarter fiscal 2026 performance, positive ongoing studies and a broad product line, bodes well for the stock.
In the year-to-date period, the Zacks Rank #3 (Hold) company’s shares have gained 24.8% compared with 1.1% growth of the industry. The S&P 500 has increased 14.2% during the said time frame.
The renowned designer, manufacturer and seller of an extensive range of innovative medical, surgical and diagnostic devices has a market capitalization of $490.3 million. The company projects 35.7% growth over the next year and expects to witness continued improvements in its business. AngioDynamics’ earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 73.1%.
Image Source: Zacks Investment Research
Reasons Favoring ANGO’s Growth
NanoKnife Driving Growth: NanoKnife continues to be a major growth engine for AngioDynamics, backed by strong clinical adoption and expanding use in prostate cancer. In the first quarter of fiscal 2026, management highlighted more than 25% revenue growth and more than 31% probe growth, driven largely by prostate procedures.
With physicians increasingly adopting the technology ahead of the new CPT Category I code going live on Jan. 1, 2026, the company is also supporting demand through a new AARP awareness campaign. Management believes NanoKnife is well-positioned to become a leading focal therapy choice for intermediate-risk prostate cancer due to strong outcomes, quick procedures and an FDA-cleared, next-generation platform.
The biggest catalyst ahead lies in reimbursement. Prostate procedures will benefit from CPT Category I codes in January 2026, with pancreatic procedures following in January 2027, setting up a stronger recurring revenue model as utilization expands. Combined with a growing installed base, rising surgeon engagement and improved clarity around payments, AngioDynamics sees NanoKnife as a differentiated and durable driver of long-term profitable growth.
Broad Product Line: AngioDynamics continues to demonstrate strong momentum across its Med Tech platforms, led by robust growth in Auryon, thrombectomy and its comprehensive oncology portfolio. In the first quarter of fiscal 2026, Auryon delivered 20.1% revenue growth, its 17th straight quarter of double-digit expansion — supported by solid adoption in both hospitals and OBLs, with the recent CE Mark contributing additional lift.
Thrombectomy remained another standout, with Mechanical Thrombectomy revenue up 41.2%, driven by 37.1% growth in AngioVac and 52.3% in AlphaVac. The expansion of the dedicated thrombectomy sales force to 50 territories highlights the company’s commitment to strengthening market penetration even without major new product launches.
Meanwhile, AngioDynamics’ broader Med Device portfolio delivered stable 2.3% growth, aligning with expectations for low-single-digit expansion. This steady performance complements the faster-growing Med Tech businesses, creating a balanced mix of innovation-led growth and recurring revenue stability. Together, these trends reflect a strengthening competitive position across oncology, vascular access and peripheral disease solutions, underscoring the company’s ability to scale utilization and capture market share across core markets.
Solid Q1 Results: AngioDynamics delivered a solid start to fiscal 2026, with first-quarter revenues rising 12.2% year over year, led by continued strength in its Med Tech segment, which grew 26% and now represents nearly half of total sales. The company also reported a narrower-than-expected adjusted loss, supported by gross margin expansion despite the impact of tariff headwinds.
A Factor That May Offset ANGO’s Gains
Macroeconomic Concerns: In the first quarter of fiscal 2026, AngioDynamics emphasized that tariffs remain the biggest external drag on margins, with $1.7 million in tariff costs weighing on gross margin by about 220 basis points. These expenses were fully expected and aligned with the company’s forecast of $4–$6 million in tariff impact for the full year.
Despite this headwind, gross margin still improved year over year, driven by stronger pricing, operational efficiencies and a mix shift toward higher-margin Med Tech products. Management also pulled forward several cost-improvement initiatives, helping blunt the effect of tariffs and demonstrating solid operational discipline.
Estimate Trend
AngioDynamics has been witnessing a positive estimate revision trend for fiscal 2026. Over the past 30 days, the Zacks Consensus Estimate for loss has narrowed 2 cents to 28 cents per share.
The Zacks Consensus Estimate for second-quarter fiscal 2026 revenues is pegged at $76.1 million, implying a 4.4% rise from the year-ago reported number. The consensus mark for fiscal second-quarter loss per share is pinned at 10 cents, implying a 150% decline year over year.
Key Picks
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , Intuitive Surgical (ISRG - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 14.28%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted EPS of $2.40, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion outperformed the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.